Personalis (PSNL) CFO and COO Aaron Tachibana Sells 51,251 Shares
Aaron Tachibana, CFO and COO of Personalis, Inc., sold 51,251 shares on June 26, 2026.
Reviewed by automated data checks against the source filing. How we make and check alerts
Aaron Tachibana, CFO AND COO at Personalis, Inc. ($PSNL), sold 51,251 shares on June 26, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $PSNL is up 10.1% after 1 week, down 8.0% after 1 month and up 20.2% to date (from the $13.02 close on Jun 26, 2026).
PSNL
Personalis, Inc.
Key Points
- Aaron Tachibana, CFO and COO of Personalis, Inc., sold 51,251 shares on June 26, 2026.
- Shares of Personalis traded near $13.02 on Saturday, with a 52-week range of $3.84 to $13.37.
- Morgan Stanley maintained a hold rating on Personalis with a $9.00 target on May 12, 2026.
Get $PSNL trade alerts by text
We text you when insiders, Congress or big funds trade $PSNL. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Personalis, Inc. alert may contain errors. Disclosures
Aaron Tachibana, the Chief Financial Officer and Chief Operating Officer of Personalis, Inc. (NASDAQGM: PSNL), sold 51,251 shares of the company on June 26, 2026. This transaction was not part of a pre-planned trading program.
Insider Buying and Selling at Personalis, Inc.
On June 26, 2026, Aaron Tachibana, CFO and COO of Personalis, Inc., executed a sale of 51,251 shares. The sale was not conducted under a Rule 10b5-1 plan. Additionally, Christopher Hall, the CEO of Personalis, also sold 100,000 shares on the same day, with some transactions being planned and others not.
Personalis, Inc. Stock Down 20.6%
Shares of Personalis, Inc. traded near $13.02 on Saturday. The company's market capitalization stands at approximately $1.36 billion. Personalis has a forward P/E ratio of -14.54, indicating it is not currently profitable. The stock has experienced a 52-week range between $3.84 and $13.37, with a 50-day moving average of $8.27 and a 200-day moving average of $8.21. The company maintains a strong liquidity position with a current ratio of 6.61 and a quick ratio of 6.31.
Analysts Set New Price Targets
On May 12, 2026, Morgan Stanley maintained its hold rating on Personalis with a price target of $9.00. BTIG also maintained a buy rating with a target of $11.00 on May 11, 2026. The consensus among seven analysts is a hold rating with an average target price of $10.86.
About Personalis, Inc.
Personalis, Inc. is a healthcare company based in Fremont, California, specializing in advanced cancer genomic tests and services. It offers products like the NeXT Personal liquid biopsy test and ImmunoID NeXT, which provide detailed insights into cancer tumors. The company collaborates with pharmaceutical firms for research and clinical trials and employs around 259 people under the leadership of CEO Christopher M. Hall.
Bottom Line
Aaron Tachibana's recent sale of shares highlights insider activity at Personalis, Inc. Investors often track such transactions for insights into company leadership's confidence. While shares traded near their 52-week high, analysts have mixed views, with targets ranging from $9.00 to $13.00. As always, remember that insider transactions are backward-looking and may not indicate current strategies.
Related Filing Alerts
Source: Aaron Tachibana's Form 4 filing on $PSNL (Jun 26, 2026). Find the original filing: PSNL Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts